BMC Cancer (Oct 2005)

Modeling the effect of age in T1-2 breast cancer using the SEER database

  • Lee Sang-Joon,
  • Royce Melanie,
  • Voordeckers Mia,
  • Vlastos Georges,
  • Van De Steene Jan,
  • Cserni Gábor,
  • Tai Patricia,
  • Vinh-Hung Vincent,
  • Storme Guy

DOI
https://doi.org/10.1186/1471-2407-5-130
Journal volume & issue
Vol. 5, no. 1
p. 130

Abstract

Read online

Abstract Background Modeling the relationship between age and mortality for breast cancer patients may have important prognostic and therapeutic implications. Methods Data from 9 registries of the Surveillance, Epidemiology, and End Results Program (SEER) of the United States were used. This study employed proportional hazards to model mortality in women with T1-2 breast cancers. The residuals of the model were used to examine the effect of age on mortality. This procedure was applied to node-negative (N0) and node-positive (N+) patients. All causes mortality and breast cancer specific mortality were evaluated. Results The relationship between age and mortality is biphasic. For both N0 and N+ patients among the T1-2 group, the analysis suggested two age components. One component is linear and corresponds to a natural increase of mortality with each year of age. The other component is quasi-quadratic and is centered around age 50. This component contributes to an increased risk of mortality as age increases beyond 50. It suggests a hormonally related process: the farther from menopause in either direction, the more prognosis is adversely influenced by the quasi-quadratic component. There is a complex relationship between hormone receptor status and other prognostic factors, like age. Conclusion The present analysis confirms the findings of many epidemiological and clinical trials that the relationship between age and mortality is biphasic. Compared with older patients, young women experience an abnormally high risk of death. Among elderly patients, the risk of death from breast cancer does not decrease with increasing age. These facts are important in the discussion of options for adjuvant treatment with breast cancer patients.